Research Article

Fetal and Maternal Outcomes of Planned Pregnancy in Patients with Systemic Lupus Erythematosus: A Retrospective Multicenter Study

Table 4

Univariate analysis of variables associated with different fetal adverse maternal outcomes.

CharacteristicsFetal lossPreterm birthIUGRFetal distress
YesNoYesNoYesNoYesNo

12231541893620727216
Disease flares during pregnancy11(91.7)41(17.7)<0.00127(50.0)25(13.2)<0.00116(44.4)36(17.4)<0.0019(33.3)43(19.9)0.1
Active lupus nephritis9(75.0)36(15.6)<0.00123(42.6)22(11.6)<0.00112(33.3)33(15.9)0.017(25.9)38(17.6)0.3
Thrombocytopenia5(41.7)18(7.8)0.0028(14.8)15(7.9)0.14(11.1)19(9.2)0.85(18.5)18(8.3)0.2
Leukopenia2(16.7)5(2.2)0.042(3.7)5(2.6)0.707(3.4)0.31(3.7)6(2.8)0.6
PIH5(41.7)24(10.4)0.00720(37.0)9(4.8)<0.00113(36.1)16(7.7)<0.00110(37.0)19(8.8)<0.001
Anti-dsDNA antibody positivity5(41.7)88(38.1)0.821(38.9)72(38.1)1.016(44.4)77(37.2)0.49(33.3)84(38.9)0.6
Anti-Ro antibody positivity8(66.7)91(39.4)0.0721(38.9)78(41.3)0.817(47.2)82(39.6)0.416(59.3)83(38.3)0.04
Anti-La antibody positivity2(16.7)31(13.4)0.78(14.8)25(13.2)0.85(13.9)28(13.5)1.03(11.1)30(13.9)0.7
LAC positivity5(41.7)14(6.1)0.0018(14.8)11(5.8)0.034(11.1)15(7.2)0.44(14.8)15(6.9)0.2
Anticardiolipin antibody positivity8(66.7)21(9.1)<0.00115(27.8)14(7.4)<0.0017(25.9)22(10.2)0.039(25.0)20(9.7)0.02
Anti-beta2 GP1 positivity2(16.7)19(8.2)0.34(7.4)17(9.0)0.72(5.6)19(9.2)0.72(7.4)19(8.8)0.8
Hypoalbuminemia6(50.0)60(26.0)0.0917(31.5)49(25.9)0.47(19.4)59(28.5)0.37(25.9)59(27.3)0.9
Hypocomplementemia9(75.0)47(20.3)<0.00117(31.5)39(20.6)0.110(27.8)46(22.2)0.36(22.2)50(23.1)0.9
Hydroxychloroquine9(75.0)117(50.6)0.129(53.7)97(51.3)0.816(44.4)46(22.2)0.311(40.7)115(53.)0.2